Literature DB >> 11106329

Determination of the designer drugs 3, 4-methylenedioxymethamphetamine, 3,4-methylenedioxyethylamphetamine, and 3,4-methylenedioxyamphetamine with HPLC and fluorescence detection in whole blood, serum, vitreous humor, and urine.

K M Clauwaert1, J F Van Bocxlaer, E A De Letter, S Van Calenbergh, W E Lambert, A P De Leenheer.   

Abstract

BACKGROUND: The popular designer drugs 3, 4-methylenedioxymethamphetamine (MDMA) and 3, 4-methylenedioxyethylamphetamine (MDEA) can be determined in serum, whole blood, and urine, but also in vitreous humor. The latter matrix is interesting when dealing with decomposed bodies in a toxicological setting.
METHODS: After extraction, chromatographic separation was achieved on a narrow-bore C(18) column by gradient elution with fluorometric detection; results were confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
RESULTS: The method was linear over the range of 2-1000 microg/L for whole blood, serum, and vitreous humor, and 0.1-5 mg/L for urine. Extraction recoveries were >70%, imprecision (CV) was 2.5-19%, and analytical recoveries were 95.5-104.4%. The limit of detection (LOD) and the limit of quantification (LOQ) were 0.8 and 2 microg/L, respectively, for whole blood, serum, and vitreous humor, and 2.5 microg/L and 0.1 mg/L, respectively, for urine. Excellent correlations between the quantitative LC-fluorescence and LC-MS/MS results were obtained. We found the following concentrations in a thanatochemical distribution study in rabbits: in serum, 5.3-685 microg/L for MDMA and from the LOQ to 14.5 microg/L for 3, 4-methylenedioxyamphetamine (MDA); in whole blood, 19.7-710 microg/L for MDMA and from the LOQ to 17.8 microg/L for MDA; in vitreous humor, 12.1-97.8 microg/L for MDMA and from the LOQ to 3.86 microg/L for MDA. In routine toxicological urine samples, concentrations ranged from LOQ to 14.62 mg/L for MDA, from LOQ to 157 mg/L for MDMA, and from LOQ to 32.54 mg/L for MDEA.
CONCLUSIONS: The HPLC method described is sensitive, specific, and suitable for the determination of MDMA, MDEA, and MDA in whole blood, serum, vitreous humor, and urine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106329

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  Immunohistochemical demonstration of the amphetamine derivatives 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in human post-mortem brain tissues and the pituitary gland.

Authors:  Els A De Letter; Marc F A Espeel; Marijke E C Craeymeersch; Willy E Lambert; Karine M Clauwaert; Riet Dams; Kjell A Mortier; Michel H A Piette
Journal:  Int J Legal Med       Date:  2003-01-25       Impact factor: 2.686

2.  3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration.

Authors:  Rebecca L Hartman; Nathalie A Desrosiers; Allan J Barnes; Keming Yun; Karl B Scheidweiler; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-11-15       Impact factor: 4.142

3.  Oxidative stress in rat retina and hippocampus after chronic MDMA ('ecstasy') administration.

Authors:  María Miranda; Francisco Bosch-Morell; Siv Johnsen-Soriano; Jorge Barcia; Inmaculada Almansa; Samuel Asensio; Javier Araiz; Angel Messeguer; Francisco J Romero
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 4.414

4.  A novel surface-enhanced Raman scattering method for simultaneous detection of ketamine and amphetamine.

Authors:  Shijiao Sun; Ming Guan; Chang Guo; Li Ma; Hao Zhou; Xiaomei Wang; Fang Mi; Jiutong Li
Journal:  RSC Adv       Date:  2020-10-06       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.